索拉非尼靶向治疗晚期肾癌的临床疗效及对不良反应的影响

The clinical efficacy of sorafenib targeted therapy for advanced renal carcinoma and its IFNluence on adverse reactions

目的探讨索拉非尼靶向治疗晚期肾癌的临床疗效及对不良反应的影响。方法60例晚期肾癌患者,随机分为实验组和对照组,各30例。对照组采用干扰素-α(IFN-α)、白细胞介素-2(IL-2)交替治疗,实验组采用索拉非尼靶向治疗。比较两组患者治疗效果、用药不良反应发生率。结果实验组患者治疗总有效率96.67%高于对照组的70.00%,差异有统计学意义(P<0.05)。实验组患者腹泻、乏力发生率分别为13.33%、16.67%,对照组分别为10.00%、10.00%,两组患者腹泻、乏力发生率比较差异无统计学意义(P>0.05)。实验组的皮疹、手足皮肤反应发生率分别为13.33%、16.67%,均高于对照组的0、0,发热发生率3.33%、恶心发生率0均低于对照组的23.33%、13.33%,差异均有统计学意义(P<0.05)。结论索拉非尼靶向治疗晚期肾癌患者的疗效,明显优于IFN-α、IL-2交替治疗,但是,采用过量索拉非尼药物治疗易引起患者出现手足皮肤反应、腹泻、皮疹等明显的毒副作用,适量索拉非尼药物治疗晚期肾癌,用药安全且可靠,可提升癌变控制率,改善患者的生活质量。

Objective To discuss the clinical efficacy of sorafenib targeted therapy for advanced renal carcinoma and its influence on adverse reactions.Methods A total of 60 patients with advanced renal carcinoma were randomly divided into experimental group and control group,with 30 cases in each group.The control group was treated with interferon-α(IFN-α)and interleukin-2(IL-2)alternately,and the experimental group was treated with sorafenib targeted therapy.The therapeutic effect and incidence of adverse drug reactions were compared between the two groups.Results The total effective rate of treatment 96.67%of the experimental group was higher than 70.00%of the control group,and the difference was statistically significant(P<0.05).The incidence of diarrhea,fatigue of the experimental group were 13.33%and 16.67%,which were 10.00%and 10.00%in the control group.There was no statistically significant difference in incidence of diarrhea,fatigue between the two groups(P>0.05).The incidence of skin rash,hand-foot skin reaction of the experimental group were 13.33%and 16.67%,which were higher than 0 and 0 of the control group,and fever rate 3.33%and nausea rate 0 were lower than 23.33%and 13.33%of the control group,and the difference was statistically significant(P<0.05).Conclusion The curative effect of sorafenib targeted therapy in patients with advanced renal cancer is significantly better than IFN-αand IL-2 alternate therapy.However,excessive use of sorafenib can easily cause hand-foot skin reactions,diarrhea,rash,etc.Moderate dose of sorafenib is safe and reliable in the treatment of advanced renal carcimoma,which can improve the control rate of cancer and improve the quality of life of patients.